Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Income from Continuing Operations came in at 16988000.0 in Q1 2026, down 65.98% YoY from 49934572.09 in Q1 2025, and down 275.8% on a QoQ basis from 9663000.0 in Q4 2025.
Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Income from Continuing Operations data on file, last reported at 16988000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 65.98% year-over-year to 16988000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24167000.0 (up 3.23% YoY) and the FY2025 annual result came in at 17414000.0, up 34.12% from the prior year.
- Income from Continuing Operations declined to 16988000.0 in Q1 2026, from 9663000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9663000.0 in Q4 2025 to a low of 16988000.0 in Q1 2026.
- A 5-year average of 9843648.82 and a median of 11967771.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 204.43% in 2025, down 154.97% in 2025.
- Tracing OVID's Income from Continuing Operations over 5 years: stood at 11504789.0 in 2022, then sank by 33.18% to 15322000.0 in 2023, then soared by 39.61% to 9253000.0 in 2024, then soared by 204.43% to 9663000.0 in 2025, then slumped by 275.8% to 16988000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16988000.0 (Q1 2026), 9663000.0 (Q4 2025), and 12158000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -16.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.99 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | -12.16 Mn |
| Jun 30, 2025 | -4.68 Mn |
| Mar 31, 2025 | -10.24 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | 8.52 Mn |
| Mar 31, 2024 | -11.69 Mn |
| Dec 31, 2023 | -15.32 Mn |
| Sep 30, 2023 | -11.25 Mn |
| Jun 30, 2023 | -12.41 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Dec 31, 2022 | -11.50 Mn |
| Sep 30, 2022 | -11.97 Mn |
| Jun 30, 2022 | -14.59 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -11.38 Mn |
| Jun 30, 2021 | -15.79 Mn |